BLFS Earnings Prediction
The chart below shows how BLFS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BLFS sees a +2.66% change in stock price 10 days leading up to the earnings, and a +7.29% change 10 days following the report. On the earnings day itself, the stock moves by -2.60%. This data can give you a slight idea of what to expect for the next quarter's release.
BLFS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
--
--
--
No Data Available
BLFS Earnings Analysis
BioLife Solutions Inc Corporation (BLFS.O) Earnings Conference Call
Positive
Cell Processing Revenue Growth: BioLife Solutions experienced significant growth in its cell processing platform, achieving a record high revenue of $74 million for the full year 2024, which is a 12% increase compared to 2023.
Gross Margin Improvement: The company reported a GAAP gross margin of 62% in 2024, up from 31% in 2023, indicating improved profitability despite a decrease in total revenue due to divestitures.
Positive EBITDA Turnaround: Adjusted EBITDA for 2024 was positive at $16 million, representing 19% of revenue, a significant turnaround from a negative $5 million in 2023.
Cash Balance Growth: BioLife's cash balance doubled to $109 million by the end of 2024, compared to $45 million in 2023, demonstrating improved financial stability and self-sufficiency.
Projected Revenue Growth: The company anticipates a revenue growth of 16% to 20% for 2025, with projected total revenue between $95.5 million and $99 million, driven primarily by the cell processing platform.
Q4 Revenue Surge: The fourth quarter of 2024 saw a 31% increase in total revenue year-over-year, with cell processing platform revenue increasing by 37%.
Strategic Divestitures Impact: BioLife's strategic divestitures have led to a cleaner balance sheet and a more focused operational approach, enhancing long-term growth potential.
Customer Base Strength: The company has established strong relationships with its top 20 customers, who represent approximately 80% of its biopreservation media revenue, indicating a solid customer base for future growth.
Negative
Revenue Decline Analysis: Total revenue in 2024 was $82 million, a significant decrease from $143 million in 2023 due to divestitures.
Q4 Revenue Decline: EVO and SAW platform revenue for Q4 was $2.4 million, a decrease of $200,000 or 8% from the same period in 2023.
Operating Expenses Increase: GAAP operating expenses for Q4 2024 were $24.8 million, slightly higher than $24.4 million in Q4 2023, indicating rising costs.
Net Loss Comparison: GAAP net loss was $2 million in Q4 2024, compared to $7.2 million in the prior year, although still a loss.
Increased Accounting Expenses: Increased accounting fees related to divestitures and SOX compliance added $900,000 to expenses in Q4 2024, impacting profitability.
R&D Expense Impact: The company anticipates increased R&D expenses in 2025, which could pressure margins despite revenue growth.
Customer Concentration Risk: The reliance on a small number of customers, with top 20 customers representing approximately 80% of BPM revenue, poses a risk to revenue stability.
Market Competition Analysis: The company has not identified any commercial freeze media used in clinical trials, indicating limited competition but also a lack of market diversification.
BLFS FAQs
How does BLFS typically perform around its earnings report dates?
Is BioLife Solutions Inc (BLFS) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BLFS Earning Call Sentiment
Earnings call transcript: BioLife Solutions Q4 2024 beats EPS forecast
BLFS.O
-0.24%Positive
The earnings call highlights strong financial performance, with a 31% YoY revenue increase in Q4 2024 and improved gross margins. Despite divestitures, the company shows a solid cash balance and reduced debt. Positive guidance for 2025 EBITDA margins and record high cell processing revenue further support a positive outlook. However, uncertainties around NIH funding and R&D investment risks temper the sentiment slightly. Overall, the financial health and optimistic guidance suggest a positive stock reaction in the short term.
